NCT01822509 2021-06-24Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNational Cancer Institute (NCI)Phase 1 Completed71 enrolled
NCT00089076 2014-05-30MDX-010 in Treating Patients With Recurrent or Refractory LymphomaNational Cancer Institute (NCI)Phase 1/2 Terminated18 enrolled 11 charts
NCT00060372 2013-03-27Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerNational Cancer Institute (NCI)Phase 1 Completed21 enrolled